Keyphrases
Clinical Spectrum
100%
Acute Kidney Injury
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Patients with Diabetes Mellitus
100%
Type 2 Diabetes Mellitus (T2DM)
33%
Type 2 Diabetic Patients
33%
Clinical Presentation
11%
Hypoxia
11%
Clinical Characteristics
11%
Computerized Database
11%
Cardiovascular Outcomes
11%
Type 2 Diabetes Mellitus Patients
11%
Kidney
11%
Diarrhea
11%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
11%
Sepsis
11%
Medical Emergency
11%
Laboratory Features
11%
Pathophysiologic Mechanisms
11%
COX-2 Inhibitors
11%
Glomerular Filtration
11%
Glomerular Filtration Rate
11%
Postmarketing
11%
Product Use
11%
Co-medication
11%
Renal Outcome
11%
Empagliflozin
11%
Marketing Information
11%
Multiple Benefits
11%
Nephrotoxic Medications
11%
Canagliflozin
11%
Glycemic Outcomes
11%
Renin-angiotensin-aldosterone System Blockers
11%
Warning Labels
11%
Medicine and Dentistry
Diabetes Mellitus
100%
Acute Kidney Injury
100%
Patient with Diabetes
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Maturity Onset Diabetes of the Young
50%
Patient with Type 2 Diabetes
37%
Hypoxia
12%
Drug Therapy
12%
Retrospective Study
12%
Cardiovascular System
12%
Diarrhea
12%
Nonsteroid Antiinflammatory Agent
12%
Sepsis
12%
Glycemic
12%
Glomerulus Filtration
12%
Glomerular Filtration Rate
12%
Empagliflozin
12%
Medical Event
12%
Canagliflozin
12%
Renin Angiotensin Aldosterone System
12%
Pharmacology, Toxicology and Pharmaceutical Science
Diabetes Mellitus
100%
Acute Kidney Failure
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Non Insulin Dependent Diabetes Mellitus
50%
Retrospective Study
12%
Hypoxia
12%
Diarrhea
12%
Sepsis
12%
Non-Steroidal Anti-Inflammatory Drug
12%
Angiotensin
12%
Renin
12%
Empagliflozin
12%
Canagliflozin
12%
Aldosterone
12%